Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LH Stock Forecast 2026-2027
$273.42
Current Price
$22.53B
Market Cap
Buy 14
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to LH Price Targets
+26.9%
To High Target of $347.00
+17.0%
To Median Target of $320.00
-1.3%
To Low Target of $270.00
LH Price Momentum
+2.5%
1 Week Change
+4.0%
1 Month Change
+24.1%
1 Year Change
+9.0%
Year-to-Date Change
-6.9%
From 52W High of $293.72
+30.6%
From 52W Low of $209.38
📊 TOP ANALYST CALLS
Did LH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if LabCorp is one of their latest high-conviction picks.
Latest LH Stock Price Targets & Analyst Predictions
Based on our analysis of 34 Wall Street analysts, LH has a bullish consensus with a median price target of $320.00 (ranging from $270.00 to $347.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $273.42, the median forecast implies a 17.0% upside. This outlook is supported by 14 Buy, 5 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Ricky Goldwasser at Morgan Stanley, suggesting a 1.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LH Analyst Ratings
14
Buy
5
Hold
0
Sell
LH Price Target Range
Low
$270.00
Average
$320.00
High
$347.00
Current: $273.42
Latest LH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2026 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $300.00 |
| Feb 24, 2026 | Piper Sandler | David Westenberg | Neutral | Maintains | $300.00 |
| Feb 18, 2026 | Baird | Eric Coldwell | Outperform | Maintains | $326.00 |
| Feb 18, 2026 | JP Morgan | Lisa Gill | Overweight | Maintains | $330.00 |
| Feb 6, 2026 | JP Morgan | Lisa Gill | Overweight | Maintains | $319.00 |
| Nov 7, 2025 | JP Morgan | Lisa Gill | Overweight | Maintains | $317.00 |
| Oct 29, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $320.00 |
| Oct 17, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $320.00 |
| Oct 17, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $325.00 |
| Oct 3, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $305.00 |
| Oct 2, 2025 | Barclays | Jack Meehan | Equal-Weight | Maintains | $290.00 |
| Jul 25, 2025 | Baird | Eric Coldwell | Outperform | Maintains | $302.00 |
| Jul 25, 2025 | Morgan Stanley | Ricky Goldwasser | Overweight | Maintains | $306.00 |
| Jul 25, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $305.00 |
| Jul 25, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $310.00 |
| Jul 25, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $300.00 |
| Jul 18, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $282.00 |
| Jul 9, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $285.00 |
| Jun 25, 2025 | Barclays | Jack Meehan | Equal-Weight | Maintains | $275.00 |
| Jun 11, 2025 | Morgan Stanley | Ricky Goldwasser | Overweight | Maintains | $283.00 |
Labcorp Holdings Inc. (LH) Competitors
The following stocks are similar to LabCorp based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Labcorp Holdings Inc. (LH) Financial Data
Labcorp Holdings Inc. has a market capitalization of $22.53B with a P/E ratio of 26.1x. The company generates $13.95B in trailing twelve-month revenue with a 6.3% profit margin.
Revenue growth is +5.6% quarter-over-quarter, while maintaining an operating margin of +10.6% and return on equity of +10.5%.
Valuation Metrics
Market Cap
$22.53B
Enterprise Value
$28.54B
P/E Ratio
26.1x
PEG Ratio
1.6x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
+5.6%
Gross Margin
+28.2%
Operating Margin
+10.6%
Net Margin
+6.3%
EPS Growth
+14.9%
Financial Health
Cash/Price Ratio
+2.4%
Current Ratio
1.4x
Debt/Equity
75.6x
ROE
+10.5%
ROA
+5.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Labcorp Holdings Inc. (LH) Business Model
About Labcorp Holdings Inc.
What They Do
Provides comprehensive laboratory services and diagnostics.
Business Model
Labcorp Holdings generates revenue by offering a wide range of diagnostic tests through its Diagnostics Laboratories and Biopharma Laboratory Services segments. It serves various clients including physicians, hospitals, and pharmaceutical companies, providing essential services for both routine and complex clinical needs.
Additional Information
The company specializes in advanced testing techniques, including gene-based diagnostics and oncology services. With a strong emphasis on innovation, Labcorp is positioned to enhance healthcare decision-making and improve patient outcomes. Its headquarters in Burlington, North Carolina, supports a vast network of patient service centers aimed at maximizing diagnostic efficiency.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
60,900
CEO
Mr. Adam H. Schechter
Country
United States
IPO Year
1990
Website
www.labcorp.comLabcorp Holdings Inc. (LH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
All You Need to Know About Labcorp (LH) Rating Upgrade to Buy
Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apr 21, 2026
By Zacks Equity Research
Tale of the Tape
LH or DHR: Which Is the Better Value Stock Right Now?
LH vs. DHR: Which Stock Is the Better Value Option?
Apr 21, 2026
By Zacks Equity Research
Tale of the Tape
Tempus AI Expands Strategic Partnership Amid Oncology Boom
TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and research.
Apr 16, 2026
By Sridatri Sarkar
Analyst Blog
Latest News
Quick Summary
LH is set to report Q1 earnings, supported by increasing diagnostics demand, new partnerships, and AI-driven tools enhancing growth in testing and consumer health sectors.
Why It Matters
Rising diagnostics demand and AI-driven tools indicate strong growth potential for LH, enhancing its competitive position and likely positively impacting earnings results.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Labcorp (LH) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing optimism about its earnings prospects, potentially suggesting stock price appreciation.
Why It Matters
Labcorp's upgrade to a Zacks Rank #2 signals bullish sentiment, indicating potential earnings growth, which could lead to increased investor interest and stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
d-wise, an Instem company, has appointed Christine Oliver as President. She has over 20 years of experience in clinical technology and previously led Beaconcure and endpoint Clinical.
Why It Matters
Christine Oliver's appointment as President could enhance d-wise's leadership and strategic direction, potentially driving innovation and growth in clinical trial technology, impacting investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Investors are comparing Labcorp Holdings (LH) and Danaher (DHR) for attractiveness in the Medical Services sector, focusing on value investment potential.
Why It Matters
The comparison between Labcorp and Danaher highlights potential investment opportunities, guiding value investors in selecting stocks with better growth prospects or undervaluation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Labcorp (NYSE: LH) has launched an AI-powered platform to accelerate analysis of Alzheimer's disease data, enhancing drug development for researchers and biopharmaceutical companies.
Why It Matters
Labcorp's AI-powered platform enhances drug development efficiency for Alzheimer's, potentially leading to faster breakthroughs and increased market competitiveness, impacting stock performance positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Labcorp has launched the first FDA-cleared rapid fentanyl test in the U.S., aiding emergency teams in quick response. The test is available through Labcorp Point of Care.
Why It Matters
The FDA clearance of Labcorp's rapid fentanyl test enhances its market position and potential revenue, addressing urgent healthcare needs and signaling innovation in diagnostics.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LH Stock
What is Labcorp Holdings Inc.'s (LH) stock forecast for 2026?
Based on our analysis of 34 Wall Street analysts, Labcorp Holdings Inc. (LH) has a median price target of $320.00. The highest price target is $347.00 and the lowest is $270.00.
Is LH stock a good investment in 2026?
According to current analyst ratings, LH has 14 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $273.42. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LH stock?
Wall Street analysts predict LH stock could reach $320.00 in the next 12 months. This represents a 17.0% increase from the current price of $273.42. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Labcorp Holdings Inc.'s business model?
Labcorp Holdings generates revenue by offering a wide range of diagnostic tests through its Diagnostics Laboratories and Biopharma Laboratory Services segments. It serves various clients including physicians, hospitals, and pharmaceutical companies, providing essential services for both routine and complex clinical needs.
What is the highest forecasted price for LH Labcorp Holdings Inc.?
The highest price target for LH is $347.00 from at , which represents a 26.9% increase from the current price of $273.42.
What is the lowest forecasted price for LH Labcorp Holdings Inc.?
The lowest price target for LH is $270.00 from Ricky Goldwasser at Morgan Stanley, which represents a -1.3% decrease from the current price of $273.42.
What is the overall LH consensus from analysts for Labcorp Holdings Inc.?
The overall analyst consensus for LH is bullish. Out of 34 Wall Street analysts, 14 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $320.00.
How accurate are LH stock price projections?
Stock price projections, including those for Labcorp Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 11:14 AM UTC